Skip to main content

Table 1 Baseline Demographics

From: Effect of 4 years of growth hormone therapy in children with Noonan syndrome in the American Norditropin Studies: Web-Enabled Research (ANSWER) Program® registry

Characteristic N Mean (SD) Median Range
Age, years     
  All subjects 120 9.2 (3.8) 9.6 1.6, 16.9
  Boys 90 9.20 (4.09) 9.6 1.6, 16.9
  Girls 30 9.24 (2.98) 9.6 2.8, 14.2
HSDS     
  All subjects 120 –2.6 (0.7) –2.6 –4.5, –1.2
  Boys 90 –2.6 (0.74) –2.44 –4.5, –1.2
  Girls 30 –2.9 (0.67) –2.88 –4.1, –1.7
Target HSDS 99 –0.3 (0.9) –0.2 –3.8, 2.0
IGF-1 SDS 73 –3.0 (1.5) –2.8 –8.2, 0.6
Bone age, years 93 7.7 (3.8) 7.8 0.5, 15.5
Maximal GH, ng/ml 34 11.7 (8.4) 10.0 0.8, 39.3
BMI 120 16.4 (2.0) 16.1 13.2, 26.9
Weight, kg 120 23.9 (9.4) 22.8 8.3, 51.6
  1. BMI, body mass index; GH, growth hormone; HSDS, height standard deviation score; SD, standard deviation.